KARS1 and cancer: LysRS can be secreted by cancer cells to induce inflammatory responses (151), whereas a more recent study showed a novel mechanism for the secretion of LysRS via exosomes or exosome-like extracellular vesicles from cancer cells, which is controlled by a caspase-8-dependent pathway (94).